Pfizer spent up to $10 billion to acquire Metsera last year, according to STAT. The company is now involving private equity firm Blackstone to help finance the deal, reflecting a trend of outside investors entering major pharmaceutical transactions.
This partnership signals the increasing appeal of obesity treatments to both pharma companies and private equity. For senior executives, the deal points to new financing models and rising competition in a high-growth therapeutic area. Further deals involving private equity could follow as the sector evolves.
